Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 9 | 0 | 9 |
| 2008 | 12 | 0 | 12 |
| 2009 | 7 | 3 | 10 |
| 2010 | 3 | 1 | 4 |
| 2011 | 10 | 3 | 13 |
| 2012 | 14 | 0 | 14 |
| 2013 | 10 | 2 | 12 |
| 2014 | 14 | 2 | 16 |
| 2015 | 12 | 1 | 13 |
| 2016 | 14 | 3 | 17 |
| 2017 | 15 | 1 | 16 |
| 2018 | 8 | 1 | 9 |
| 2019 | 13 | 1 | 14 |
| 2020 | 11 | 3 | 14 |
| 2021 | 10 | 0 | 10 |
| 2022 | 17 | 0 | 17 |
| 2023 | 17 | 0 | 17 |
| 2024 | 9 | 4 | 13 |
| 2025 | 9 | 2 | 11 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Safety and effectiveness of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease - A SEER-Medicare study. J Geriatr Oncol. 2026 May; 17(4):102971.
-
Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [18F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials. Integr Cancer Ther. 2026 Jan-Dec; 25:15347354251410182.
-
Multimerization approach to improve a cell surface plectin binding cancer stem cell targeted peptoid drug-lead. Bioorg Chem. 2026 05; 172:109578.
-
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge. Nat Commun. 2026 Jan 14; 17(1):1726.
-
Radiation Doses to Cardiac Substructures Predict Elevation in High-sensitivity Cardiac Troponin T Levels in Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2026 Mar 15; 124(4):1124-1136.
-
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. Lancet Oncol. 2025 Oct; 26(10):1357-1369.
-
Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. Med. 2025 Oct 10; 6(10):100752.
-
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
-
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib. JCO Precis Oncol. 2025 May; 9:e2500047.
-
Dichotomous roles of ACBD3 in NSCLC growth and metastasis. Oncogene. 2025 Jul; 44(25):2078-2090.